Greater Chicago Specialty Physicians — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$47,190	21
2024	Research	$79,654	8
2023	Research	$58,759	8
2022	Research	$10,598	4
2021	Research	$18,893	5

Breakdown

Who paid Research payments · program years 2021–2025

E.R. Squibb & Sons, L.L.C. $177,772 23 payments
Amgen Inc. $31,665 4 payments
Novartis Pharmaceuticals Corporation $3,107 3 payments
Argenx US, Inc. $2,550 16 payments

Studies the money was for Research payments · program years 2021–2025

Phase III Study -SLE #2 - A Phase 3, Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants with Active Systemic Lupus Erythematosus (SLE) (POETYK SLE-2) $27,217 2 payments
A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE) (POETYK SLE-1) $25,439 2 payments
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Nave to Biologic Disease-modifying Anti-rheumatic Drugs $25,373 2 payments
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Na ve to Biologic Disease-modifying Anti-rheumatic Drugs $23,618 1 payment
Phase III PsA (primary WK16 driving Submission) - A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants with Active Psoriatic Arthritis who are Na ve to Biologic Disease-modify $23,065 2 payments
Ph2b In Subjects with SLE $18,609 2 payments
Phase III SLE - A Phase 3, Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants with Active Systemic Lupus Erythematosus (SLE) (POETYK SLE-1) $18,302 1 payment
P2b SLE $13,056 2 payments
Phase III PsA #2 (Wk52 driving submission) - A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants with Active Psoriatic Arthritis who are Na ve to Biologic Disease-modifying A $11,368 1 payment
A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE) $11,263 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.